We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

18 hedge funds and large institutions have $1.69M invested in Evoke Pharma in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 2

13% more funds holding

Funds holding: 16 → 18 (+2)

0.03% less ownership

Funds ownership: 6% → 5.97% (-0.03%)

28% less capital invested

Capital invested by funds: $2.35M → $1.69M (-$664K)

Holders
18
Holders Change
+2
Holders Change %
+12.5%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$35.5K
2
CAN
Cetera Advisor Networks
California
+$19.6K
3
BlackRock
BlackRock
New York
+$5.95K
4
Victory Capital Management
Victory Capital Management
Texas
+$5.19K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.31K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$3.84K
2
Morgan Stanley
Morgan Stanley
New York
-$1.34K

EVOK Hedge Fund Activity: Q1 2020 in Review

18 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2020, worth a combined $1.69M — down 28% from $2.35M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new EVOK positions and 0 closed out — a net gain of 3 holders — while 3 added to existing stakes and 2 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $35.5K. The largest seller was UBS Group, cutting an estimated $3.84K.

  • 18 institutional investors held Evoke Pharma (EVOK) as of Q1 2020, up from 16 in Q4 2019.
  • Funds reported $1.69M of Evoke Pharma stock for Q1 2020, down 28% quarter-over-quarter.
  • 3 funds opened new Evoke Pharma positions in Q1 2020 and 0 closed out, a net change of +3 holders.
  • The largest Evoke Pharma buyer in Q1 2020 was Citadel Advisors, an estimated $35.5K added.
  • The largest Evoke Pharma seller in Q1 2020 was UBS Group, an estimated $3.84K sold.

Based on aggregated 13F filings for Q1 2020.